KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Raw Materials: 2016-2025

Historic Raw Materials for Acadia Pharmaceuticals (ACAD) over the last 10 years, with Sep 2025 value amounting to $77.8 million.

  • Acadia Pharmaceuticals' Raw Materials rose 84.41% to $77.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.8 million, marking a year-over-year increase of 84.41%. This contributed to the annual value of $69.7 million for FY2024, which is 122.73% up from last year.
  • Acadia Pharmaceuticals' Raw Materials amounted to $77.8 million in Q3 2025, which was down 7.05% from $83.7 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' Raw Materials' 5-year high stood at $83.7 million during Q2 2025, with a 5-year trough of $1.5 million in Q2 2021.
  • Its 3-year average for Raw Materials is $47.9 million, with a median of $53.5 million in 2024.
  • Per our database at Business Quant, Acadia Pharmaceuticals' Raw Materials plummeted by 43.83% in 2021 and then surged by 934.36% in 2024.
  • Over the past 5 years, Acadia Pharmaceuticals' Raw Materials (Quarterly) stood at $6.2 million in 2021, then decreased by 16.25% to $5.2 million in 2022, then skyrocketed by 501.34% to $31.3 million in 2023, then skyrocketed by 122.73% to $69.7 million in 2024, then surged by 84.41% to $77.8 million in 2025.
  • Its Raw Materials was $77.8 million in Q3 2025, compared to $83.7 million in Q2 2025 and $76.5 million in Q1 2025.